---
title: "Jupiter Neurosciences prices registered direct offering at USD 2 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287105760.md"
description: "Jupiter Neurosciences has priced a registered direct offering of 7,142,858 common shares, aiming for gross proceeds of approximately $2 million. The closing is anticipated around May 21, 2026, pending customary conditions, with D. Boral Capital serving as the exclusive placement agent."
datetime: "2026-05-20T18:38:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287105760.md)
  - [en](https://longbridge.com/en/news/287105760.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287105760.md)
---

# Jupiter Neurosciences prices registered direct offering at USD 2 million

-   Jupiter Neurosciences priced a registered direct offering of 7,142,858 common shares for gross proceeds of about $2 million. \* Closing is expected on or about May 21, 2026, subject to customary conditions. \* D. Boral Capital is acting as exclusive placement agent. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605201438PRIMZONEFULLFEED9724124) on May 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [JUNS.US](https://longbridge.com/en/quote/JUNS.US.md)

## Related News & Research

- [Jupiter Neurosciences Signs Multiple Material Agreements](https://longbridge.com/en/news/270661735.md)
- [Cboe Global Markets Declares Second-Quarter 2026 Dividend | CBOE Stock News](https://longbridge.com/en/news/286469933.md)
- [Atossa says (Z)-endoxifen Duchenne muscular dystrophy review accepted for publication](https://longbridge.com/en/news/287117555.md)
- [Lee to manage Hoffmann publications under five‑year agreement with quarterly fees](https://longbridge.com/en/news/287123083.md)
- [ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory](https://longbridge.com/en/news/286821171.md)